ArticleBrain sciences2025
Survival Prediction in Brain Metastasis Patients Treated with Stereotactic Radiosurgery: A Hybrid Machine Learning Approach.
Article in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identifying Prognostic Factors in Brain Metastasis Patients Using MRI Morphological Features: A Machine Learning and Survival Analysis Approach.Diagnostics (Basel, Switzerland) · 2026Article
- Hybrid Deep Learning for Survival Prediction in Brain Metastases Using Multimodal MRI and Clinical Data.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAccurate survival prediction for brain metastasis patients undergoing stereotactic radiotherapy (SRT) is crucial for personalized treatment planning and improving patient outcomes. This study aimed to develop a machine learning model to estimate survival times, providing clinicians with a reliable tool for making informed decisions based on individual patient characteristics. The goal was to compare the performance of multiple algorithms and identify the most effective model for clinical use.
methodsWe applied a hybrid machine learning approach to predict survival in brain metastasis patients treated with SRT, utilizing real-world data. Four algorithms-XGBoost, CatBoost, Random Forest, and Gradient Boosting-were compared within a meta-model framework to identify the most accurate for survival prediction. Model performance was evaluated using metrics such as MSE, MAE, MAPE, and C index.
resultsXGBoost outperformed all other algorithms, achieving an MSE of 0.14%, MAE of 0.10%, and MAPE of 0.093%, with a high C-index of 100%. CatBoost showed reasonable performance, while Gradient Boosting had higher error rates (MSE of 6.99%, MAE of 21.04%, MAPE of 19.29%). Random Forest performed the weakest, with the highest MSE (14.39%), MAE (30.23%), and MAPE (33.58%).
conclusionInputting relevant clinical variables into the model enables clinicians to obtain highly accurate survival predictions for patients with brain metastasis. This enhances clinical decision making by providing a more precise understanding of expected outcomes. The XGBoost-based hybrid model showed exceptional accuracy in predicting survival for brain metastasis patients after SRT, offering valuable support for clinical decision making. Integrating machine learning into clinical practice can improve treatment planning and personalize care for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.